albaconazole
Small moleculeexperimental
Albaconazole is an experimental triazole antifungal. It has potential broad-spectrum activity. The drug blocks a number of CYP450 liver enzymes. — Wikipedia
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2004 (NCT00199264)
Timeline
Indications
Studied for
Mechanism of action
- 14-alpha sterol demethylase Cyp51AINHIBITOR
cyp51A inhibitor
- Lanosterol 14-alpha demethylaseINHIBITOR
Lanosterol 14-alpha demethylase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](n1cnc2cc(Cl)ccc2c1=O)[C@](O)(Cn1cncn1)c1ccc(F)cc1F- Mol. weight
- 431.83 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAlbaconazole ↗
- ChEMBLCHEMBL298817 ↗
Also known as
- 7-chloro-3-(2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl)quinazolin-4(3h)-one
- albaconazole
- albaconazole
- albaconazole
- albaconazole
- albaconazole
- ur 9825
- ur-9825
- ur-9825
- ur-9825
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01039883 | Phase 1 | Nov 23, 2009 | GlaxoSmithKline, Stiefel Laboratories |
| NCT01014962 | Phase 1 | Aug 24, 2009 | GlaxoSmithKline, Stiefel Laboratories |
| NCT00730405 | Phase 2 | Jul 1, 2008 | GlaxoSmithKline, Stiefel Laboratories |
| NCT00199264 | Phase 2 | Jun 1, 2004 | J. Uriach and Company |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 0 | 2 | 2008 |
| Stiefel Laboratories | For profit | 3 | 3 | 2 | 2008 |
| J. Uriach and Company | For profit | 1 | 1 | 1 | 2004 |
3 organizations
Page 1 / 1